大黄黄连泻心汤、理中丸对消炎痛型胃溃疡寒热证模型影响的相关性研究
详细信息    本馆镜像全文|  推荐本文 |  |   获取CNKI官网全文
摘要
目的:通过观察大黄黄连泻心汤、理中丸对消炎痛型胃溃疡寒、热证模型相关性的影响,探讨该模型的形成机制,阐明寒、热性质不同方剂对消炎痛型胃溃疡寒、热证模型的作用机理及方证相应规律,为规范临床评价标准提供可靠的实验依据。
     方法:采用消炎痛注射法复制大鼠胃溃疡模型,同时施加“寒、热”因素(冰水+0.3%氢氧化钠、8%干辣椒粉+60%乙醇混合液)建立消炎痛型胃溃疡寒、热证模型,并观察寒、热方剂大黄黄连泻心汤、理中丸对其影响。检测相关微观指标:酶免法检测模型血清ET、PDGF、PAF、MOT含量;硝酸还原酶法检测模型血清NO含量;酶免法检测模型胃组织TGF-a、EGF含量;酶免法检测下丘脑组织5-HT、NE含量;免疫组化法观察Bax、Bcl-2灰度值并进行密度定量分析。结果:1、在ET方面,与空白组比较,各模型组均明显升高,有显著性差异(P<0.01),尤以寒消组升高明显,理中丸干预后,寒消理组与寒消组、单寒理组与单寒组比较含量明显降低,有统计学意义(P<0.01或P<0.05);2、在NO方面,与空白组比较,单消组、寒消组、单寒组含量明显降低,热消组、单热组含量明显升高,有统计学意义(P<0.01或P<0.05)。大黄黄连泻心汤干预后,热消大组与热消组、单热大组与单热组比较含量降低,有统计学意义(P<0.01或P<0.05);3、在PAF、PDGF方面,与空白组比较,模消组、寒消组、单寒组、热消组、单热组均可使PAF、PDGF明显升高(P<0.01或P<0.05),尤以热消组、单热组升高明显,有统计学意义(P<0.05);大黄黄连泻心汤干预后,热消大组与热消组、单热大组与单热组比较,PAF含量降低,PDGF含量明显升高,有统计学意义(P<0.01或P<0.05);理中丸干预后,寒消理组与寒消组、单寒理组与单寒组比较,PDGF含量明显升高,有统计学意义(P<0.01或P<0.05)。4、在EGF、TGF-a方面,与空白组比较,模消组、寒消组、单寒组、热消组、单热组均有不同程度的下降,有统计学意义(P<0.01),其中热消组、寒消组EGF含量下降明显,有统计学意义(P<0.01或P<0.05),理中丸干预后,寒消理组与寒消组、单寒理组与单寒组比较,EGF、TGF-a含量明显升高,有统计学意义(P<0.01),大黄黄连泻心汤干预后,热消大组与热消组、单热大组与单热组比较,EGF、TGF-a含量明显升高,有统计学意义(P<0.01或P<0.05)5、在MOT方面,与空白组比较,模消组、寒消组、热消组、单热组比较明显升高,尤以热消组升高明显,有统计学意义(P<0.01)。大黄黄连泻心汤干预后,热消大与热消、单热大与单
     热比较,MOT含量明显降低,有统计学意义。6、在5-HT方面,与空白组比较,寒消组、单寒组明显升高,与热消组比较差异明显,有统计学意义(P<0.01),理中丸干预后,寒消理组与寒消组、单寒理组与单寒组比较含量明显降低,有统计学意义(P<0.01或P<0.05)7、在NE方面,与空白组比较,除单寒组外,各模型组均有同程度的升高,尤以热消组升高明显,有统计学意义(P<0.01或P<0.05),大黄黄连泻心汤干预后后,热消大组与热消组、单热大组与单热组比较含量降低,有统计学意义(P<0.01或P<0.05)。8、在Bcl-2方面,寒消组与空白组比较,阳性表达增强;寒消理与寒消比表达更强;单寒组与空白组比较表达减弱;单寒理与单寒比表达增强;热消组与空白组比较,阳性表达增强;热消大与热消比表达增强;单热与空白比表达减弱;单热大与单热比表达增强。在Bax方面,各模型组与空白组比较,灰度值降低,阳性表达增强;寒消理与寒消、热消大与热消比较,灰度值升高,阳性表达减弱,有显著性差异。
     结论:
     1、本课题采用消炎痛注射与寒(冰水、氢氧化钠)、热(辣椒+乙醇)因素结合,成功建立了胃溃疡寒、热证模型;寒、热因素可加重胃溃疡的形成与损伤。
     2、ET、5-HT可作为胃溃疡寒证模型的微观指标NO、MOT、PAF、PDGF、NE、TGF-a、EGF可作为胃溃疡热证的微观指标。
     3、理中丸对相应寒证模型有选择性,通过下调ET、5-HT含量;上调EGF、TGF-a、PDGF含量,改善抗氧化能力和调节炎性因子释放,可能是理中丸治疗胃溃疡寒证的作用机制,体现了方证相应的证治规律。
     4、大黄黄连泻心汤对相应热证模型有选择性,通过下调NO、MOT、NE、PAF含量,升高EGF、TGF-a、PDGF含量,调节胃肠激素、抑制炎症反应、调节炎性因子释放,可能是大黄黄连泻心汤治疗胃溃疡热证的作用机制,体现了方证相应的证治规律。
     5、大黄黄连泻心汤与理中丸通过上调Bcl-2和下调Bax表达,进而抑制胃溃疡模型细胞凋亡的表达,这可能是促进胃溃疡损伤黏膜修复机制之一。
Objective: Through observing Dahuang huanglian xiexin decoction and li zhong pill `s influence on indomethacin gastric ulcer model cold or heat types` relativity, we intend to explore the mechanism of the model, understand cold or heat different prescriptions` mechanism of action and orderliness for gastric ulcer model induced by indomethacin, in order to provide credible experimental evidences for clinical practice evaluation criteria.
     Methods: The gastric ulcer models were copied by Indomethacin injection method, at the same time imposing "cold or hot" factor (ice water +0.3% NaOH, 8% dried chili powder +60% ethanol mixture). Establish the cold or heat syndrome modles of indomethacin ulcer model, and to observe the impact of cold or heat prescription Dahuang huanglian xiexin decoction and Lizhong pill. Detect the Related micro-target: The content of model serum ET, PDGF, PAF, MOT was detected by enzyme immunoassay; the content of model serum NO by Nitrate reductase; the content of model gastric tissue TGF-a, EGF by enzyme immunoassay;content; the content of hypothalamus 5-HT and NE by enzyme immunoassay. Besides, The gray value of Bax and Bc1-2 was detected and analyzed in density.
     Results: 1.In the ET side, compared with the control group, the model group were significantly higher, there was significant difference (P <0.01), especially in Hanxiao groups, after the intervention of Lizhong pill, Hanxiaoli compared with Hanxiao group while Danhanli group compared with Danhan group, the content of ET is significantly lower, with statistical significance (P <0.01 or P <0.05); 2, In the NO side, compared with the control group, the model group were significantly lower, with statistically significant (P <0.01 or P <0.05), especially in Rexiao group was decreased significantly, after the intervention of Dahuang huanglian xiexin decoction, Rexiaoda group compared with Rexiao group while Danreda group compared with Danre group the content of NO decreased, with statistically significant (P <0.01 or P <0.05); 3, In the PAF, PDGF side, comparison with the control group, Moxiao Hanxiao Danhan Rexiao Danre groups can increased significantly (P <0.01 or P <0.05), especially in Rexiao Danre groups, with statistical significance(P <0.05); after the intervention of Dahuang huanglian xiexin decoction, Rexiaoda group compared with Rexiao group while Danreda group compared with Danre group, PAF decreased and PDGF were significantly higher, with statistically significant (P <0.01 or P <0.05); after the intervention of Lizhong pill, Hanxiaoli group compared with Hanxiao group while Danhanli group compared with Danhan group, PDGF were significantly higher, with statistically significant (P <0.01 or P <0.05).4. Considering EGF, TGF-a, Moxiao group, Rexiao group, Hanxiao group, Danre group and Danhan group decreased in different degree compared with the Kongbai group with the statistical significance (P <0.01). And the content of EGF of Rexiao group and Hanxiao group decreased significantly with the statistical significance (P <0.01, or P <0.05). After the intervention of Lizhong pill, the content of EGF and TGF-a of Hanxiaoli group and Danhanli group increased significantly compared with Hanxiao group and Danhan group with the statistical significance (P <0.01). After the intervention of Dahuang huanglian xiexin decoction, the content of EGF and TGF-a of Rexiaoda group and Danreda group increased significantly compared with Rexiao group and Danre group with the statistical significance (P <0.01, or P <0.05). 5. The Moxiao group, Hanxiao group, Rexiao group and Danre group increased significantly in MOT compared to Kongbai group, especially the Rexiao group with the statistical significance (P <0.01). After the intervention of Dahuang huanglian xiexin decoction, the content of MOT of Rexiaoda group and Danreda group decreased significantly compared to Rexiao group and Danre group with the statistical significance. 6. The Hanxiao group and Danhan group increased significantly in 5-HT compared to Kongbai group with the statistical significance (P <0.01). After the intervention of Lizhong pill, the content of Danxiao group and Danhan group decreased significantly compared to Hanxiao group and Danhan group with the statistical significance(P <0.01, or P <0.05). 7. In the aspect of NE content, all groups increased differently compared to Kongbai group except Danhan group, especially the Rexiao group with the statistical significance(P <0.01, or P <0.05). After the intervention of Dahuang huanglian xiexin decoction, the content of MOT of Rexiaoda group and Danreda group decreased significantly compared to Rexiao group and Danre group with the statistical significance(P <0.01, or P <0.05). 8. In the Bc1-2 and Bax content, compared to Kongbai group, the model group decreased on Bax expression, Danhan group and Danre group of Bcl-2 expression increased significantly (P <0.01 or P <0.05). The expression of Hanxiao group, Rexiao group, Hanxiaoli group and Rexiaoda group increased especially the Hanxiaoli group and Rexiaoda group; the Danhan group, Danhanli group, Danreda group and Danre group decreased especially the Danhanli group and Danreda group with the statistical significance.
     Conclusions:
     1. This subject uses Indomethacin injection with the cold (ice water + NaOH) or heat (chilli + ethanol) factors established the cold or heat syndrome gastric ulcer disease model successfully. Cold or heat factors can increase the formation and injury of gastric ulcer model.
     2, ET、5-HT can be a microcosmic indicator of cold syndrome gastric ulcer . NO, MOT, PAF, PDGF, NE, TGF-a, EGF can be used as microcosmic indicators of heat syndrome gastric ulcer.
     3.Lizhong Pill is selective to the cold syndrome model, through making down the content of ET ,5-HT, PDGF, and making up the content of EGF, TGF-a, The mechanism of Lichong Pill to treat cold syndrome peptic ulcer disease may be improving the antioxidant capacity and regulation of inflammatory cytokine release, reflecting the law of Recipe corresponding to syndrome.
     4. Dahuang huanglian xiexin decoction is selective to corresponding models, and is able to Regulate gastrointestinal hormones, inhibit inflammation and regulate inflammatory cytokine release by raising the content of EGF, TGF-a and reducing the content of NO, MOT, NE, PAF. This may be mechanism of Dahuang huanglian xiexin decoction on heat of ulcer disease, reflecting treatment of the corresponding square law of evidence.
     5. Dahuang huanglian xiexin decoction and the Lizhong Pill can inhibit the expression of Gastric ulcer model cell death by raising Bc1-2 and reducing Bax. This may be one of Gastric mucosal repair mechanisms for damage.
引文
[1]江绍基.消化溃疡治疗沿革.中华消化杂志,1991,11(5):249
    [2]李慧吉.心身Ⅰ号抗应激性溃疡的实验研究.中医杂志,1997,10(10)
    [3]李乾构,王自立.中医胃肠病学[M].北京:中国医药科技出版社,2004(第一版):453-454.
    [4]张春燕.中医辨证治疗胃溃疡体会.吉林中医药,2007,27(1):13
    [5]阮玉东.辨证治疗消化性溃疡68例疗效观察.浙江中医学院学报, 2000,24(3):27-28
    [6]杨伟钢,何海国.中医辨证治疗消化性溃疡162例.国际医药卫生导报2005 ,11(22) :77—78
    [7]王细凤.辨证治疗消化性溃疡60例.湖南中医杂志,2004,20(1):35-36
    [8]陈泽民.辨证治疗难治性消化性溃疡80例.陕西中医,1987,(7):305
    [9]陈月秋,刘建和.辨证治疗虚证消化性溃疡105例.湖南中医学院学报,1995,15(2):15
    [10]刘振宇.辨证施治加乳没三七珍珠散治疗溃疡病149例分析.江西中医药,1989,(2):20
    [11]戴克敏.姜春华治疗消化性溃疡的经验.山西中医,2005,21(1):6-8
    [12]张燕.调补行瘀法治疗胃及十二指肠溃疡128例.山东中医学院学报,1989,(6):33
    [13]田海河.中医药抗消化性溃疡复发的研究.中医杂志,1992,(8):33-35
    [14]沈晓艳,陈光均,马贵同.治疗消化性溃疡经验述要.辽宁中医学院学报,2000,2(2):113
    [15]王伟明,祝德军.三期辨治消化性溃疡经验.山东中医杂志,1997,16(7):323
    [16]余在先.消化性溃疡内镜下中医分型论治体会.山西临床医药,2000,9(4):294-295
    [17]唐志鹏,许鑫梅.辨治消化性溃疡的经验.中国中西医结合脾胃杂志,2000,8(2):96
    [18]王小平,瞿慕东.微观辨证治疗胃及十二指肠溃疡病体会.湖南中医杂志,2001,17(5):40
    [19]颜会兰,李应全,等.复方溃疡散治疗消化性胃溃疡的实验与临床研究.山东中医药大学学报,2000,24(3):188-190
    [20]韦麟.黄芪建中汤加味治疗消化性溃疡50例.吉林中医药,2004,24(11)
    [21]魏宏斌,唐博民.加味乌贝散治疗消化性溃疡80例疗效观察.山西中医学院学报,2007,8(2):26
    [22]马锡金,于世良,陈萍.胃康胶囊治疗幽门螺杆菌相关性消化性溃疡56例临床研究.中医杂志,2006,47(3):187-189
    [23]张炜宁,李家邦,王霞.健胃愈疡颗粒抗消化性溃疡复发的临床研究.湖南中医药导报,2003,9(9):15-16
    [24]朱爱华.中药自拟方治疗消化性溃疡的临床观察.湖北中医杂志,2007,29(10):35
    [25]勇.半夏泻心汤加减治疗消化性溃疡60例疗效观察.云南中医中药杂志,2003,24(5):23-24
    [26]王庆国.以血瘀证为切入点进行中医证候规范及其生物学基础的研究.江西中医学院学报,2004,16(5):5-10
    [27]王世民,王永吉,郭晓峰等.关于方剂辨证的一些思考.山西中医,2002,18(4):1-3
    [28]李茹柳,陈艳芬,陈蔚文.左金丸方证相应动物模型建立的回顾及其对方证研究的意义.广州中医药大学学报,2005,22(3):236-238
    [29]中国中西医结合学会消化系统疾病专业委员会.慢性胃炎的中西医结合诊治方案(草案).中国中西医结合杂志,2005,25(2):172-175
    [30]许自诚,傅关孺.胃寒证、胃热证与胃液中PGE2和62keto2PGF1α的关系及机理探讨.中国中西医结合杂志,1994,(基础理论增刊):76-78
    [31]傅关孺,许自诚.胃寒热辨证与胃液中K、Na浓度关系的探讨.北京中医杂志,1991,(3):16-17
    [32]周夕林,张关平,许冠荪等.胃病辨证分型与胃电图变化的规律初探.中医杂志,1985,(3):63-64
    [33]许自诚,任登先,王必舜等.胃寒、热证与胃内温度的关系.中西医结合杂志,1983,3(6):351-352
    [34]戴建林,钟青英,叶柞泉等.十二指肠溃疡尿素酶、胃黏膜相和证型的关系.中国医药学报,1995,10(3):20-21
    [35]危北海.102例CP与中医辨证的关系.中西医结合杂志,1990,10(5):534
    [36]傅关孺,万邦均.胃寒热证与胃黏膜象关系初探.安徽中医学院学报,2008, 27(4):13-14
    [37]牛凤云,田庆玲,吴春萍.脾胃虚寒型胃溃疡动物模型的初步探讨.中国中西医结合急救杂志,2005,12(2):84-85
    [38]陈小野.实用中医证候动物模型学[M].北医协和联合出版社, 1993:286
    [39]陈艳芬,陈蔚文,李茹柳.大鼠寒热型胃黏膜损伤模型的研究.中药药理与临床,2002,18(2):44-45
    [40]黎敬波,葛金文.胃溃疡胃实寒、实热证模型大鼠经穴辐射热、pH值及氧分压的检测研究.湖南中医学院学报,1998,18(30):56
    [41]邱赛红,李飞艳,尹健康等.两种大鼠脾胃虚寒模型制备方法的比较研究.湖南中医学院学报,2004,24(6):30-31
    [42]山丽梅,赵艳玲,孔维军,洪炜,刘志国,肖小河.大鼠胃热证动物模型的建立.2009,15(2):30-32
    [43]李小梅,黄雪群等.采用红外热扫描成像系统研究归胃经寒性中药对胃热证大鼠的热效应.激光生物学报,2007,16(2):236-237
    [44]黎敬波,葛金文.胃溃疡胃实寒、实热证模型大鼠经穴辐射热、pH值及氧分压的检测研究.湖南中医学院学报, 1998, 18 (30): 56
    [45]陈小野,邹世洁,王震,藤静如,王少军.大鼠长期热证造模的胃黏膜病理观察.甘肃中医学院学报,1999,16(3):11-13
    [46]陈小野,邹世洁,王震.大鼠长期热证造模的舌扫描电镜观察.广西中医药,1998,21(2):42
    [47]裴仁九,江川,陈国成等.硫糖铝和盐酸雷尼替丁合用对四种大鼠胃溃疡模型的影响.解放军药学学报,2000,16(5):239-242
    [48]胡伏莲.消化性溃疡发病机制的现代理念.中华消化杂志,2005,25(3):189-190
    [49]李岩.消化性溃疡的药物治疗进展.中国实用内科学杂志,2007,(27)1:24-25
    [50]徐世平,王孟薇,龙纬缔.幽门螺杆菌感染与人胃癌相关研究.中华消化杂志,1997, 17(4):212
    [51] Nomura A, Stemmermann GN, Chyou PH, et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration[J].Ann InternMed, 1994,120(2):977-981
    [52]汪鸿志.现代消化性溃疡病学[M].人民军医出版社,1999:167-169
    [53]李慧吉.心身1号抗应激性溃疡的实验研究.中医杂志,1997,10
    [54]徐斌,王效道.心身医学-心理生理医学的基础与临床[M].北京:中国医药科技出版社,1990:91-93
    [55] Levenstein S.The very model of a modern etiology:A biopsychosocial view of peptic ulcer[J].Psychoso-matic Medicine,2000,62:176-185
    [56] Levenstein S.Psychosocial factors in peptic ulcer and inflammatory bowel Disease[J].J of Consulting and Clinical Psychology,2002,70 (3):739-750
    [57]戴瑞鸿.内科新理论与新技术.上海:上海科学技术出版社,1999:3
    [58]李慧吉.心身Ⅰ号抗应激性溃疡的实验研究.中医杂志,1997:10
    [59] Huang JQ,SridharS,Hunt RH,et al.Role of Helicobacter pylori infect-ion and non-steroidal anti-inflammatory drugs in peptic ulcer disease : a meta-analysis. Lancet,2002,359(9300):14-22
    [60] Yuan Y,Padolt, Hurn FH1 Pcp tic ulecr discasc today[J].Natclinpnacl Gastrocntcrol Hcpatol,2006,3(2):80-891
    [61] DincerD,Duman A, Dickici H, et al. NSA ID2related upper gastrointestinal bleeding: are rosk factors considered during prophylaxis? [J] Int J Chin Pract, 2006, 60(3):546-548
    [62] Criffin MR. Ep idemiology of nonsteroidal anti2inflammaltory drug-as-sociated gastrointestinal injury[J]. Am J Med,1998,104(3A): 23S-29S
    [63] Mersereau WA, Hinchey EJ. Prevention of phenylbutazone ulcer in the rat by glucose, role of a glycop rivic recep tor system [J].Am J Physiol, 1982,242:G429-G432
    [64]石湘云,姚松潮,杨晔.血管活性物质与临床[M] .北京:北京医科大学中国协和医科大学联合出版,2000,34(71):81-85
    [65] Yanagisawa M , Kurihara H , Kimura S. A novel potent vasocons- trictor prptide by vascular endothelial cells. Nuture. 1988 , 332 (6163) :411
    [66]李兆坤,湛先保,许国铭.胃黏膜损伤与保护—基础与临床[M].上海:上海科学技术出版社,2001,363(365):306-350
    [67] Bodesson M, Tmebrandt K,Ameklo-Nobin,etal. Effeetofeooling- onvaseular smooth muscle response to endothelinin human and rat veins.IntAngiol ,1995,16(4):262-268
    [68] Pruess KL . Vascular and mucosal effects of endothelin 1 and endothelin 3 in the rat stomach .Gastroenterology,1991,100:A387
    [69] Toyokuni S,Tanaka Z Hattori Z et a1.Quantitative immunohisto chemical determination of8-hydroxy-2'-deoxyguanosine by a monoclonal antibody N45 I:Its application to ferric nitrilotriacetate—induced renalcarcinogenesis model[J].Lab Invest,1997,76(3):365-374
    [70] Takeuchi koji , Okabe Susumu. Mechanism of gastric alkaline response in thestomach after damage , roles of nitric oxide and prostaglandins [J ] . Digest DisSci ,1995,40:8652871
    [71] Cho C H. Current roles of nitric oxide in gastrointestinal disorders. J Physiol Paris ,2001,95:253
    [72]刘建平,王文智,白建乐等.胃喜康提高大鼠胃溃疡愈合质量及抗复发的实验研究.中国中医基础医学杂志,2004,10(4):30-31
    [73]柳丽,张洪泉.丹参饮对胃溃疡大鼠部分猫膜防御因子的影响.中药新药与临床药理,2005,16(1):35-38
    [74] Anderson BO et al.Surg Gynecol Obstet,1991,171:415-421
    [75]李兆申,湛先保,许国铭.胃黏膜损伤与保护一基础与临床.上海:上海科技出版社,2004:107-111
    [76] Wallace JL,et al.Gastroenterology,1988,93:765
    [77] Bessin PBJ,et al.Eur J Pharmacol,1983,86:403
    [78] Rosam A-C,et al.Nature,1986,319:54
    [79] Whittle BJR,et al.Am J Physiol,1986,251:G772
    [80] Droy-Lefaix MT,et al.Gastroenterology,1988,94,5(2):A104
    [81] Bureau M,et al.In:Braquet JR.eds.Ginkgonlides.Francc:Prous Science Publishers,1988:161
    [82] Hernandez LA,et al.Am J Physiol,1987,253:H699
    [83] Wallace JL et al.Gastroenterology,1988,93:765
    [84] Wallance JL,et al.Gastroenterology,1988,94:5(2):A485
    [85] Soybel DL,et al.Am J Surg,1988,155:180
    [86] Cucada M,et al.Gastroenterology,1988,94,5(2):A81
    [87] Vargaftig BB,et al.Br Med Bull,1987,43(2):312
    [88] Terashita Z,et al.Eur J Pharmacol,1985,109:257
    [89] Szabo S,Khomenko T,Gombos Z,et al.Review article :transcription factors and growth factors in ulcer healing.Aliment Pharmacol Ther,2000,14 (Suppl):33-43
    [90] Piazuelo E,LanasA,Jimenez P,et al.In vitro wound repair by human gastric fibroblasts:implications for ulcer healing.Dig Dis Sci,1998,43: 1230-1240
    [91] Milani S, Calabro A. Role of growth factors and their recep tors ingastric ulcer healing[ J ]. Microsc Res Tech, 2001, 53 ( 5) : 360- 371
    [92] Watanabe S, HiroseM, Wang XE, et al. Ep ithelial - mesenchy2mal interaction in gastricmucosal restoration[ J ]. J Gastroenterol,2000, 35 Supp l 12: 65-68
    [93] Vinter - Jensen L. Pharmacological effects of ep idermal growthfactor ( EGF) with focus on the urinary and gastrointestinal tracts[ J ]. APMIS Supp l,1999,93: 1-42
    [94] Konturek P C, Konturek S J, Brzozowski T, et al. Ep idermalgrowth and transforming growth factor-alpha: role in p rotectionand healing of gastric mucosal lesions [ J ]. Eur J GastroenterolHepatol, 1995,7(10): 933-937
    [95] Konturek PC, Ernst H, Brzozowski T, et al. Exp ression of ep i2dermal growth factor - alpha after exposure of rat gastric mucosato stress[ J ]. Scand Gastroenterol,1996,31(3):209-216
    [96] Tepperman BL, SoperBD. Effect of sialoadenectomy on gastric mu2cosal integrity and growth in the rat[ J ]. Dig Dis Sci, 1990,35(8):943 - 949
    [97]李兆申.胃黏膜损伤与保护-基础与临床[M].上海:上海科学技术出版社,2004:269-274
    [98] Tamawski A ,Santos A M ,Hanke S ,et al. Quality of gastric ulcer healing is it influenced by antiulcer drugs. Scand J Gastroenterol Suppl, 1995, 208:9-13
    [99] Konturek JW,Bielansk iW , Konturek ST, et al.Gut,1989,30(9): 1194-1200
    [100]Cartlidge SA , Elder JB. Br J Cancer,1989,60(5):657-660
    [101]Brazozowski SJ, Konturdk J,Majka A, et al. EGF,Polyamines,and p rostaglandins in healing of stress - induced gastric lesions in rats. Dig Dis Sci,1993,38(2):276-288
    [102]W illiam s L T.Science,1989,243(4898):1564-1570
    [103]许春娣.表皮生长因子在消化性溃疡愈合中的作用.国外医学·儿科学分册,1997,24(3):123-126
    [104]Konturek PC,Konturek Sj,Brzozowski T et al. Epidermal growth and transforming growth factor alpha: Role in protection and healing of gastric mucosal lesions[J].Eur-J-Gast-roenterol- Hepatol,1995,7 (10): 933-937
    [105]时昭红,张介眉,周慧芳等.促愈颗粒对胃溃疡实验大鼠胃黏膜表皮生长因子及其受体表达的影响.中国中西医结合消化杂志,2007,15(1):25-27
    [106]刘红.转化生长因子对消化性溃疡的修复作用研究进展.国际消化病杂志, 2006,26(5):320-322
    [107]李长军,张惠,王革革等.消溃灵对消化性溃疡及萎缩性胃炎患者血清胃液表皮生长因子含量的影响.新中医,2001,33(9):12-13
    [108]Karevina TG,Shevchuk IM Effect of blockaders of biogenic amine receptors on experimental ulcer devel opment Famakol Toksikol (Russian),1988,51(4):56-60
    [109]梅琦等.应激对大鼠胃窦及十二指肠5-HT细胞内5-HT含量的影响.第四军医大学学报,1991,12(1):53-55
    [110]韩济生等.中枢神经介质概论.北京科学出版社,1980:22-120
    [111]张建福等.电刺澈室旁核对大鼠应澈性胃黏膜损伤的影响.生理学报待发表.
    [112]张建福等.侧脑室注射去甲肾上腺素对大鼠应激性胃溃疡的影响.徐州医学院学报,1992,l2(3):210-214
    [113]王苑本.消化性溃疡研究现状[J].新消化病学杂志,1996,4(3):123
    [114]严宝霞.药物临床各论[M].北京:北京医科大学出版社,1999
    [115]萧树东,刘文忠.消化性溃疡治疗重大变革.中华内科杂志,1996,35(1):3
    [116]Vlasblom V.Effects of a new effervescent cimetidine formulation on gastric acidity inhealthy subjects North J Med.1991,38:147
    [117]陈旻湖.抑酸剂在消化性溃疡治疗中的作用.中华消化杂志,2008,28(7):442-443
    [118]戴德银.实用新药特药手册[M]13版.北京人民军医出版社,2005:706
    [119]陈新谦,金有豫,汤光.新编药物[M]115版.北京:人民卫生出版社, 2004:401
    [120]Watanable K,Murakami K,Sato R,et al.Antimicrob Agents Chemot her,2004,48:4582-4588